KRAS-IN-43

KRAS-IN-43 (Compound 9) is a pan-KRAS inhibitor with IC50 values of 0.15 μM, 0.14 μM, and 0.47 μM against KRASG12V, KRASG12C and wild-type KRAS, respectively. KRAS-IN-43 disrupts the interaction between KRAS and cRAF, and inhibits ERK phosphorylation. KRAS-IN-43 is promising for research of KRAS mutation-related cancers (such as pancreatic cancer, colorectal cancer, and lung cancer) [1].

Product Specifications

UNSPSC

12352005

Target

ERK; Ras

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt

Field of Research

Cancer

Smiles

C#CC1=C(C=CC2=CC(O)=CC(C(N3CCC4=C(C3)C=CC=C4OCC56CCCN5CCC6)=O)=C21)F

Molecular Formula

C30H29FN2O3

Molecular Weight

484.56

References & Citations

[1]Aladinskiy V, et al. Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping, and Biological Evaluation[J]. ACS Medicinal Chemistry Letters, 2025.